Bharat Biotech develop's India's first Covid-19 vaccine candidate with ICMR-NIV, gets DCGI nod for human trials | India News -
You are here
Home > India >

Bharat Biotech develop’s India’s first Covid-19 vaccine candidate with ICMR-NIV, gets DCGI nod for human trials | India News

HYDERABAD: Vaccine maker Bharat Biotech on Monday said it has successfully developed India’s first vaccine candidate for Covid-19 in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV).
Called Covaxin, the indigenous, inactivated vaccine has also got approval from the Indian drugs regulator, Drug Controller General of India (DCGI), for conducting phase I and II human clinical trials that will begin across the country in July 2020, Bharat Biotech said.
The SARS-CoV-2 virus strain was isolated from an asymptomatic Covid-19 patient at NIV, Pune, and transferred to Bharat Biotech, which grew and replicated the virus and developed the vaccine candidate at its BSL-3 (Bio Safety Level-3) high containment facility manufacturing facility at Genome Valley in Hyderabad.
Bharat Biotech chairman and managing director Dr Krishna Ella, said the results from preclinical studies have been promising and show extensive safety and effective immune responses. “Expedited through national regulatory protocols, the company accelerated its objective in completing the comprehensive pre-clinical studies,” he said.
Apart from Covaxin, Bharat Biotech is already partnering with US-based vaccine maker FluGen and virologists at the University of Wisconsin-Madison to develop an intranasal vaccine – CoroFlu. It has also inked an exclusive deal with the Thomas Jefferson University of Philadelphia for the development of a new vaccine candidate for Covid-19, which has been invented at Jefferson using an existing deactivated rabies vaccine as a vehicle for coronavirus proteins.

Leave a Reply

%d bloggers like this: